Fast Facts
Generally Healthy
18-45 Years Old
Compensation Provided
Conducted in Atlanta, GA
Study Background
This study aims to evaluate the safety and immune response of an experimental inactivated rotavirus vaccine, Inactivated Rotavirus CDC-9, in adults to potentially improve vaccine effectiveness and prevent severe illness caused by rotavirus infection.
Rotavirus is a contagious virus that primarily affects infants and children, causing symptoms such as severe diarrhea, vomiting, fever, and dehydration. In some cases, the illness can be severe enough to require hospitalization or even result in death. While two FDA-approved vaccines are currently available to protect against rotavirus, both are administered orally and contain live virus. However, these vaccines have shown limited effectiveness in preventing severe illness in certain populations, potentially due to the method of administration. This study, conducted at Emory University, seeks to address this gap by testing an experimental inactivated rotavirus vaccine, which may offer a safer and more effective alternative. By assessing the safety profile and immune response generated by the vaccine over a 9-10 month period, researchers hope to improve preventative measures against rotavirus infection in adults.
Study Background
This study aims to evaluate the safety and immune response of an experimental inactivated rotavirus vaccine, Inactivated Rotavirus CDC-9, in adults to potentially improve vaccine effectiveness and prevent severe illness caused by rotavirus infection.
Rotavirus is a contagious virus that primarily affects infants and children, causing symptoms such as severe diarrhea, vomiting, fever, and dehydration. In some cases, the illness can be severe enough to require hospitalization or even result in death. While two FDA-approved vaccines are currently available to protect against rotavirus, both are administered orally and contain live virus. However, these vaccines have shown limited effectiveness in preventing severe illness in certain populations, potentially due to the method of administration. This study, conducted at Emory University, seeks to address this gap by testing an experimental inactivated rotavirus vaccine, which may offer a safer and more effective alternative. By assessing the safety profile and immune response generated by the vaccine over a 9-10 month period, researchers hope to improve preventative measures against rotavirus infection in adults.
Additional Information
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18-45
- Generally healthy
- Healthy weight (BMI between 18.0 – 35.9 kg/m2)
- Agree to use one acceptable primary form of contraception
- Able to attend 9 clinic visits
Exclusion Criteria:
- Previously received a rotavirus vaccine or been diagnosed with rotavirus within the past 10 years
- Active skin condition (e.g., eczema or other chronic dermatitis) or an open lesion (e.g., laceration, abrasion), scar, tattoo, or rash
- Clinically significant history of or active/ongoing gastrointestinal disease
Currently pregnant or breastfeeding
As a participant, you can receive up to $940.
There is no cost for you to participate in our research study.
